Neurogene Inc. announced its second quarter 2025 financial results on August 11, 2025, reporting a net loss of $22.016 million for the quarter, compared to $18.492 million for the same period in 2024. Research and development expenses increased to $19.366 million from $15.744 million in the prior year quarter, primarily due to the NGN-401 program.
As of June 30, 2025, Neurogene held approximately $274.5 million in cash, cash equivalents, and short-term investments. The company reiterated its projection that existing resources are sufficient to fund operations into early 2028, following a reallocation of capital to support pivotal trial activities for NGN-401.
Neurogene also reaffirmed significant progress in its NGN-401 program for Rett syndrome, including the completion of dosing for the Phase 1/2 trial and the receipt of written agreement from the U.S. FDA on the key elements of the Embolden™ registrational trial design. Trial initiation activities for Embolden™ are currently underway, with updated clinical efficacy and safety data from the Phase 1/2 trial anticipated in the second half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.